Incidence and Impact of ICU-acquired Diaphragm Weakness

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

ICU survivors are at an increased risk of hospital and ICU readmission. Among the complications of ICU stay, diaphragmatic dysfunction is common, with a prevalence of 60 to 80%, and is associated with increased mortality and prolonged hospital stays. Furthermore, several studies have reported that the observation of impaired respiratory muscle function upon ICU discharge is associated with a poor long-term prognosis. However, the incidence and prognostic impact of persistent diaphragmatic dysfunction at ICU discharge have never been evaluated. The measurement of dyspnea, a composite evaluation of respiratory muscle function, has not been assessed for predicting prognosis upon ICU discharge. The hypothesis of the project is that the presence of ICU-acquired diaphragmatic dysfunction at ICU discharge is associated with a poorer prognosis within 90 days.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years

• Invasive or non-invasive respiratory support (ventilation, high-flow oxygen therapy, whatever the reason) for at least 48 hours.

• Weaning from respiratory support (invasive or not) within the last 24 hours.

• Patient (or trusted person/relative) informed and not opposed to the study.

Locations
Other Locations
France
Médecine intensive Réanimation
RECRUITING
Paris
Contact Information
Primary
Martin Dres, MD,PHD
martin.dres@aphp.fr
0142167809
Time Frame
Start Date: 2024-07-29
Estimated Completion Date: 2028-01-29
Participants
Target number of participants: 194
Treatments
Patients weaned from mechanical or non invasive ventilation
Adults admitted to ICU receiving either invasive mechanical ventilation for at least 48 hours, non-invasive ventilation or high-flow humidified oxygen therapy for at least 48 hours, and who have been weaned from ventilatory support within the last 24 hours.
Related Therapeutic Areas
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov